CA3248625A1 — Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock

USPTO Abstract

Compositions for intravenous infusion of istaroxime in human patients suffering from pre-cardiogenic shock or cardiogenic shock are disclosed. Likewise, methods of administering istaroxime to individuals exhibiting symptoms of, or having been diagnosed with pre-cardiogenic shock or cardiogenic shock are disclosed. In particular, disclosed herein is a method of treating or preventing pre-cardiogenic shock or cardiogenic shock in an individual by administering to the individual a dosage regimen of istaroxime by intravenous infusion for up to 24 hours.